Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Lemonaid Health
→
23andMe

Acquisition · Cash and stock · ME · announced Oct 22, 2021

View in network
  1. Announced

    Oct 22, 2021

  2. Closed

    Nov 1, 2021

Economics

Cash and stock

$400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)

Target

Lemonaid Health

Mental Health · Consumer wellness

HQ San Francisco, CA · Founded 2013

Telehealth platform with women's health focus

  • SEC EDGAR EX-99.1 — 23andMe/Lemonaid merger agreement (Oct 22, 2021)
  • Globe Newswire — acquisition closing (Nov 1, 2021)
  • Crunchbase - crunchbase.com/organization/lemonaid-health

Acquirer

23andMe (ME)

General Wellness

HQ Sunnyvale, CA

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Combined consumer genetics with telehealth and mail-order pharmacy to expand into personalized virtual care

Evidence ladder

Dual-source corroborationValue disclosed
  1. Primary (regulatory / filing)

    SEC EDGAR EX-99.1 (23andMe–Lemonaid merger agreement, Oct 22, 2021)

    SEC EDGAR filings (ticker locator)
  2. Secondary (press / IR)

    Globe Newswire closing release (Nov 1, 2021)

  3. Primary (regulatory / filing)

    SEC EDGAR 8-K EX-99.1 (merger agreement, Oct 22, 2021) https://www.sec.gov/Archives/edgar/data/1804591/000119312521305409/d231996dex991.htm

    Open source
  4. Primary (regulatory / filing)

    SEC EDGAR 8-K EX-99.1 (closing, Nov 1, 2021) https://www.sec.gov/Archives/edgar/data/1804591/000119312521316240/d247525dex991.htm

    Open source

Limitations

  • $400M purchase price (25% cash, 75% 23andMe Class A stock), subject to customary adjustments per SEC EX-99.1 (Oct 22, 2021)

Valuation peers · Mental Health

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Mental Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Other verified deals by 23andMe

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by 23andMe are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Lemonaid Health (Mental Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 4 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.